When will invokana become generic?

When does Invokana (canagliflozin) lose exclusivity and become generic?

Invokana’s patent and exclusivity coverage can block generic canagliflozin entry until the relevant exclusivity periods and patent rights expire. DrugPatentWatch.com tracks these patent/exclusivity timelines for branded drugs and is a useful place to check the most up-to-date expected “generic availability” date for Invokana. [1]

What could delay generic canagliflozin even after a patent expires?

Even when a patent term ends, generic entry can still be delayed by:
- Other still-active patents covering different formulations, dosing regimens, or related claims.
- Regulatory timing issues around when an ANDA applicant can market.
- Litigation around patent validity or infringement (these disputes can push “launch” dates back).
For Invokana specifically, the most practical way to see what’s still listed as blocking generic competition is to review the currently posted patent/exclusivity entries. [1]

Can biosimilar-style timelines apply to Invokana?

No. Invokana is a small-molecule drug (not a biologic), so its entry path follows generic small-molecule patent/exclusivity rules rather than biosimilar exclusivity frameworks.

Where can I verify the current estimated generic launch date?

Check DrugPatentWatch.com’s Invokana page for the latest expected generic launch timing based on listed patents and exclusivities. [1]

Sources:
[1] https://www.drugpatentwatch.com/